Sprouts (SFM) Q4 2025 earnings review
Growth Engine Stalls: Negative Comp Guidance Overshadows Q4
Sprouts hit a wall in Q4. While total sales grew 8% driven by new stores, comparable store sales decelerated sharply to +1.6% (down from +11.7% in Q1). The outlook is stark: management guides for *negative* comps (-3% to -1%) in Q1 2026 and flat earnings for FY26. Despite a 53rd operating week adding an estimated $0.21 to 2026 EPS, the full-year guidance of $5.28-$5.44 suggests core earnings power is retreating from FY25's $5.31 peak.
🐂 Bull Case
The growth story has shifted entirely to new units. Sprouts opened 13 stores in Q4 (37 for the year) and plans 40+ openings in 2026. With 477 stores today, the runway for footprint expansion remains the primary revenue driver.
Operations generated $716M in cash for FY25, funding a massive $472M in share buybacks (4.0 million shares). With zero balance on the $600M revolver, the balance sheet is pristine.
🐻 Bear Case
The trajectory is alarming: Comps fell from +11.7% in Q1 to +1.6% in Q4, with Q1 2026 guidance forecasting a contraction of -3% to -1%. The 'health enthusiast' boom appears to be over or facing severe macro headwinds.
FY26 EPS guidance ($5.28-$5.44) looks flat vs FY25 ($5.31). However, FY26 includes a 53rd week worth ~$0.21. Excluding that one-time benefit, implied core earnings are declining YoY despite 40+ new stores.
⚖️ Verdict: 🔴
Bearish. The sharp reversal in comparable sales from double-digits to negative territory in just 12 months is a major red flag. While unit economics and cash flow remain good, the core business momentum has broken, and FY26 guidance implies organic contraction masked by a 53-week calendar.
Key Themes
Comp Sales Cliff
Comparable store sales have collapsed. After posting +10.2% in Q2 and +5.9% in Q3, Q4 dropped to +1.6%. Guidance for Q1 2026 calls for negative comps (-3% to -1%). Management cites 'strong prior year comparisons' and a 'dynamic macro environment,' but the speed of deceleration suggests a fundamental shift in consumer behavior or traffic.
Aggressive Store Expansion
New store openings are accelerating to compensate for slowing comps. Sprouts opened 13 stores in Q4 alone, reaching 477 total. The target for 2026 is 40+ new stores. This physical expansion drove total sales up 8% in Q4 despite the anemic 1.6% comp.
Core Margin Compression Risk
FY26 EBIT guidance is $675-$695M. Compare this to FY25 Actual EBIT of $686M. Management expects zero EBIT growth at the midpoint, despite adding 40+ stores and a 53rd week (worth ~$28M EBIT). This implies the core 52-week base business is seeing profit degradation.
Shareholder Returns
Capital allocation remains aggressive. Sprouts repurchased 4.0 million shares in FY25 for $472M. A new $1 billion buyback program was authorized. With $257M in cash and strong operating cash flow ($716M), buybacks will likely be the primary tool to support EPS in a flat-growth environment.
53rd Week Impact
FY26 is a 53-week year. Management explicitly estimates this extra week contributes ~$200M in sales, $28M in EBIT, and $0.21 in EPS. This optical boost masks the underlying weakness in the 2026 guidance.
Q4 Gross Margin Stagnation
After quarters of expansion, Gross Margin in Q4 was effectively flat/down slightly at 38.0% vs 38.1% in the prior year (calculated from Q4 financials: $816M/$2,148M vs $760M/$1,996M). The leverage story from sales volume is fading as comps slow.
Other KPIs
Strong year-over-year growth of +42% vs FY24 ($3.75). However, momentum slowed significantly in Q4 (+17% YoY) compared to Q1 (+62% YoY). The growth curve has flattened.
Robust generation, up from $645M in FY24. Covered CapEx ($224M) three times over, allowing for aggressive buybacks ($472M). Cash flow remains the healthiest part of the financial picture.
Expenses rose 6.2% YoY, slightly slower than revenue growth of 7.6%, showing minor leverage. However, with negative comps guided for Q1, SG&A deleverage is a high risk for early 2026.
Guidance
Reversing. A dramatic shift from positive to negative territory. This implies significant traffic or basket deterioration compared to the +11.7% lap from Q1 2025.
Decelerating/Stagnant. At midpoint ($5.36), EPS is practically flat vs FY25 ($5.31). Excluding the estimated $0.21 benefit from the 53rd week, core EPS guidance is ~$5.15, implying a year-over-year decline.
Decelerating. Significantly lower than the 14% growth achieved in FY25. Growth is now entirely dependent on new store openings (40+) rather than organic same-store improvements.
Stable/Decline. Midpoint ($685M) is effectively equal to FY25 ($686M). Considering the 53rd week adds ~$28M, the underlying 52-week EBIT is guided down to ~$657M, a ~4% decline.
Key Questions
Negative Comp Drivers
Q1 2026 guidance calls for negative 1-3% comps. Is this solely due to lapping the tough 11.7% compare, or are you seeing active deflation or traffic loss in specific categories?
Core Profitability Erosion
Excluding the 53rd week benefit, 2026 guidance implies a decline in both EBIT and EPS despite 40+ new stores. What is driving this negative operating leverage—promotional intensity, wages, or occupancy costs?
Macro Impact
You referenced a 'dynamic macro environment.' Are you seeing trade-down behavior from your core health-enthusiast customer, or is this weakness coming from the more marginal shoppers acquired during the boom?